// Johann von Felden 1, * , Kornelius Schulze 1, * , Till Krech 2 , Florian Ewald 3 , Björn Nashan 3 , Klaus Pantel 4 , Ansgar W. Lohse 1 , Sabine Riethdorf 4 and Henning Wege 1 1 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 2 Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 3 Department for Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 4 Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany * These authors have contributed equally to this work Correspondence to: Henning Wege, email: h.wege@uke.de Keywords: hepatocellular carcinoma, CTC, BCLC A, liquid biopsy, precision medicine Received: July 13, 2017 Accepted: July 31, 2017 Published: September 23, 2017 ABSTRACT Background: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM-positive circulating tumor cells (CTC) as liquid biomarker to identify patients with high risk of recurrence after liver resection. Methods: 61 patients undergoing resection between 2011 and 2015 were consecutively enrolled. Blood specimens were obtained prior to surgery and processed with the CellSearch TM system, detecting EpCAM-positive CTC. The primary endpoint was recurrence-free survival (RFS). Results: 13 women and 44 men (63.6 ± 11.1 years) were finally evaluated. CTC-positive patients had a significantly higher risk of recurrence with a hazard ratio (HR) of 2.3 (p=0.027), and a shorter RFS compared to CTC-negative patients (5.0 ± 1.5 vs. 12.0 ± 2.5 months, p=0.039). As expected, incomplete resection (R1) was also associated with shorter RFS (HR=2.6, p=0.035), but vascular invasion was not. However, the predictive power of CTC status was independent of R1. Conclusion: Bloodstream detection of CTC prior to curative-intended liver resection discloses an elevated risk of HCC recurrence and could identify patients, who might benefit from adjuvant treatment.
No takes yet. Share an insight, caveat, or question.
Felden et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: